Evaluation and Prognostication of Gd-EOB-DTPA MRI and CT in Patients With Macrotrabecular-Massive Hepatocellular Carcinoma
- PMID: 37840197
- DOI: 10.1002/jmri.29052
Evaluation and Prognostication of Gd-EOB-DTPA MRI and CT in Patients With Macrotrabecular-Massive Hepatocellular Carcinoma
Abstract
Background: Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is highly aggressive. Comparing the diagnosis ability of CT and gadoxetate disodium (Gd-EOB-DTPA) MRI for MTM-HCC are lacking.
Purpose: To compare the performance of Gd-EOB-DTPA MRI and CT for differentiating MTM-HCC from non-MTM-HCC, and determine the prognostic indicator.
Study type: Retrospective.
Subjects: Post-surgery HCC patients, divided into the training (N = 272) and external validation (N = 44) cohorts.
Field strength/sequence: 3.0 T, T1-weighted imaging, in-opp phase, and T1-weighted volumetric interpolated breath-hold examination/liver acquisition with volume acceleration; enhanced CT.
Assessment: Three radiologists evaluated clinical characteristics (sex, age, liver disease, liver function, blood routine, alpha-fetoprotein [AFP] and prothrombin time international normalization ratio [PT-INR]) and imaging features (tumor length, intratumor fat, hemorrhage, arterial phase peritumoral enhancement, intratumor necrosis or ischemia, capsule, and peritumoral hepatobiliary phase [HBP] hypointensity). Compared the performance of CT and MRI for diagnosing MTM-HCC. Follow-up occurred every 3-6 months, and nomogram demonstrated the probability of MTM-HCC.
Statistical tests: Fisher test, t-test or Wilcoxon rank-sum test, area under the curve (AUC), 95% confidence interval (CI), multivariable logistic regression, Kaplan-Meier curve, and Cox proportional hazards. Significance level: P < 0.05.
Results: Gd-EOB-DTPA MRI (AUC: 0.793; 95% CI, 0.740-0.839) outperformed CT (AUC: 0.747; 95% CI, 0.691-0.797) in the training cohort. The nomogram, incorporating AFP, PT-INR, and MRI features (non-intratumor fat, incomplete capsule, intratumor necrosis or ischemia, and peritumoral HBP hypointensity) demonstrated powerful performance for diagnosing MTM-HCC with an AUC of 0.826 (95% CI, 0.631-1.000) in the external validation cohort. Median follow-up was 347 days (interquartile range [IQR], 606 days) for the training cohort and 222 days (IQR, 441 days) for external validation cohort. Intratumor necrosis or ischemia was an independent indicator for poor prognosis.
Data conclusion: Gd-EOB-DTPA MRI might assist in preoperative diagnosis of MTM-HCC, and intratumor necrosis or ischemia was associated with poor prognosis.
Evidence level: 4 TECHNICAL EFFICACY: Stage 2.
Keywords: Gd‐EOB‐DTPA; computed tomography; hepatocellular carcinoma; macrotrabecular‐massive; magnetic resonance imaging.
© 2023 International Society for Magnetic Resonance in Medicine.
References
-
- Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76(2):182‐188.
-
- Zhang HD, Li XM, Zhang YH, et al. Evaluation of preoperative microvascular invasion in hepatocellular carcinoma through multidimensional parameter combination modeling based on Gd‐EOB‐DTPA MRI. J Clin Transl Hepatol 2023;11(2):350‐359.
-
- Calderaro J, Meunier L, Nguyen CT, et al. ESM1 as a marker of macrotrabecular‐massive hepatocellular carcinoma. Clin Cancer Res 2019;25(19):5859‐5865.
-
- Luo M, Liu X, Yong J, et al. Preoperative prediction of macrotrabecular‐massive hepatocellular carcinoma based on B‐Mode US and CEUS. Eur Radiol 2023;33(6):4024‐4033.
-
- Huang M, Liao B, Xu P, et al. Prediction of microvascular invasion in hepatocellular carcinoma: Preoperative Gd‐EOB‐DTPA‐dynamic enhanced MRI and histopathological correlation. Contrast Media Mol Imaging 2018;2018:9674565.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
